首页> 美国卫生研究院文献>Frontiers in Oncology >Dosimetric and Radiobiological Comparison of External Beam Radiotherapy Using Simultaneous Integrated Boost Technique for Esophageal Cancer in Different Location
【2h】

Dosimetric and Radiobiological Comparison of External Beam Radiotherapy Using Simultaneous Integrated Boost Technique for Esophageal Cancer in Different Location

机译:同步整合Boost技术在不同位置食管癌外照射治疗的剂量学和放射生物学比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objectives: To compare treatment plans of intensity modulated radiotherapy (IMRT), volumetric modulated arc radiotherapy (VMAT), and helical tomotherapy (HT) with simultaneous integrated boost (SIB) technique for esophageal cancer (EC) of different locations using dosimetry and radiobiology.Methods: Forty EC patients were planned for IMRT, VMAT, and HT plans, including 10 cases located in the cervix, upper, middle, and lower thorax, respectively. Dose-volume metrics, conformity index (CI), homogeneity index (HI), tumor control probability (TCP), and normal tissue complication probability (NTCP) were analyzed to evaluate treatment plans.Results: HT showed significant improvement over IMRT and VMAT in terms of CI (p = 0.007), HI (p < 0.001), and TCP (p < 0.001) in cervical EC. IMRT yielded more superior CI, HI and TCP compared with VMAT and HT in upper and middle thoracic EC (all p < 0.05). Additionally, V30 (27.72 ± 8.67%), mean dose (1801.47 ± 989.58cGy), and NTCP (Niemierko model: 0.44 ± 0.55%; Lyman-Kutcher-Burman model: 0.61 ± 0.59%) of heart in IMRT were sharply reduced than VMAT and HT in middle thoracic EC. For lower thoracic EC, the three techniques offered similar CI and HI (all p > 0.05). But VMAT dramatically lowered liver V30 (9.97 ± 2.84%), and reduced NTCP of lungs (Niemierko model: 0.47 ± 0.48%; Lyman-Kutcher-Burman model: 1.41 ± 1.07%) and liver (Niemierko model: 0.10 ± 0.08%; Lyman-Kutcher-Burman model: 0.17 ± 0.17%).Conclusions: HT was a good option for cervical EC with complex target coverage but little lungs and heart involvement as it achieved superior dose conformity and uniformity. Due to potentially improving tumor control and reducing heart dose with acceptable lungs sparing, IMRT was a preferred choice for upper and middle thoracic EC with large lungs involvement. VMAT could ameliorate therapeutic ratio and lower lungs and liver toxicity, which was beneficial for lower thoracic EC with little thoracic involvement but being closer to heart and liver. Individually choosing optimal technique for EC in different location will be warranted.
机译:目标:比较强度调制放射疗法(IMRT),体积调制弧线放射疗法(VMAT)和螺旋断层放射疗法(HT)与同时集成增强(SIB)技术治疗食管癌(EC)的方案方法:已计划对40例EC患者进行IMRT,VMAT和HT计划,其中分别有10例位于子宫颈,上,中和下胸部。分析剂量-体积指标,一致性指数(CI),均一性指数(HI),肿瘤控制概率(TCP)和正常组织并发症概率(NTCP)以评估治疗方案。结果:与宫颈癌EC的CIRT(p = 0.007),HI(p <0.001)和TCP(p <0.001)相比,IMRT和VMAT有显着改善。与上,中胸EC的VMAT和HT相比,IMRT产生的CI,HI和TCP更好(所有p <0.05)。此外,IMRT中心脏的V30(27.72±8.67%),平均剂量(1801.47±989.58cGy)和NTCP(Niemierko模型:0.44±0.55%; Lyman-Kutcher-Burman模型:0.61±0.59%)比胸中EC的VMAT和HT。对于下胸部EC,这三种技术提供了相似的CI和HI(所有p> 0.05)。但是VMAT显着降低了肝脏的V30(9.97±2.84%),并降低了肺的NTCP(Niemierko模型:0.47±0.48%; Lyman-Kutcher-Burman模型:1.41±1.07%)和肝脏(Niemierko模型:0.10±0.08%; Lyman-Kutcher-Burman模型:0.17±0.17%)。结论: HT是宫颈EC的理想选择,靶标覆盖范围复杂,但很少有肺和心脏受累,因为它具有优异的剂量一致性和均匀性。由于有可能改善肿瘤控制和减少心脏剂量,同时保留肺部保留,因此IMRT是肺部累及的上胸和中胸EC的首选选择。 VMAT可以改善治疗率,降低肺和肝毒性,这对于胸廓受累少,但更靠近心脏和肝脏的胸部EC有利。将有必要针对不同位置的EC分别选择最佳技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号